Ovarian cancer is high recurrence and mortality malignant tumor. The most common ovarian cancer was High-Grade Serous Ovarian Cancer. However, High-Grade Serous Ovarian Cancer organoid is rare, which organoid with patient immune microenvironment and blood vessels even absence. Here, we report a novel High-Grade Serous Ovarian Cancer organoid system derived from patient ovarian cancer samples. These organoids recapitulate High-Grade Serous Ovarian Cancer organoids' histological and molecular heterogeneity while preserving the critical immune microenvironment and blood vessels, as evidenced by the presence of CD34 + endothelial cells. Whole exome sequencing identifies key mutations ( CSMD3 , TP53 , GABRA6 ). Organoids show promise in testing cisplatin sensitivity for patients resistant to carboplatin and paclitaxel, with notable responses in cancer proteoglycans and p53 ( TP53 ) signaling, like ACTG / ACTB1 / AKT2 genes and BBC3 / MDM2 / PERP . Integration of immune microenvironment and blood vessels enhances potential for novel therapies like immunotherapies and angiogenesis inhibitors. Our work may provide a new detection system and theoretical basis for ovarian cancer research and individual therapy.
Keyphrases
- high grade
- low grade
- endothelial cells
- stem cells
- gene expression
- squamous cell carcinoma
- genome wide
- end stage renal disease
- chronic kidney disease
- dna methylation
- signaling pathway
- coronary artery disease
- prognostic factors
- climate change
- machine learning
- deep learning
- transcription factor
- cell therapy
- cardiovascular events
- mesenchymal stem cells
- quantum dots
- study protocol
- replacement therapy